Logo
x

Search category

Subscribe Now

All Posts by Date

Merck Reports Results of Arpraziquante in P-III Clinical Trial for the Treatment of Schistosomiasis

Merck Reports Results of Arpraziquante in P-III Clinical Trial for the Treatment of Schistosomiasis

  • November 17, 2021
Viatris and Biocon Launch Semglee (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) for the Treatment of Diabetes in the US

Viatris and Biocon Launch Semglee (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) for the Treatment of Diabet...

  • November 17, 2021
Sotio Signs a Multiple Agreement with LegoChem Biosciences to Develop Novel Therapeutics for the Treatment of Solid Tumors

Sotio Signs a Multiple Agreement with LegoChem Biosciences to Develop Novel Therapeutics for the Treatment of Solid Tumors

  • November 17, 2021
Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021

Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021

  • November 17, 2021
AbbVie's Skyrizi (risankizumab) Receives EC's Approval for the Treatment of Active Psoriatic Arthritis

AbbVie's Skyrizi (risankizumab) Receives EC's Approval for the Treatment of Active Psoriatic Arthritis

  • November 17, 2021
Biogen's Vumerity (diroximel fumarate) Receives the EC's Approval for the Treatment of Relapsing-Remitting Multiple Sclerosis

Biogen's Vumerity (diroximel fumarate) Receives the EC's Approval for the Treatment of Relapsing-Remitting Multiple Sclerosis

  • November 17, 2021
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.